Benzinga | Oct 26, 2020 04:31PM EDT

DURECT Corporation To Participate In ROTH Capital Partners Healthcare Event 'Covid-19 Therapeutics in Development' Oct. 28

CUPERTINO, Calif., Oct. 26, 2020 /PRNewswire/ -- DURECT Corporation (NASDAQ:DRRX) today announced that it will partipate in the ROTH Capital Healthcare Event, "Covid-19 Therapeutics in Development," taking place on Wednesday, October 28, 2020. The ROTH Healthcare and Biotechnology team are hosting the webinar to discuss key therapies in development to treat COVID disease.

The Webinar includes three sessions: "Immune Modulators to Ameliorate COVID Disease 1," "Direct Antivirals and Other Agents Against SARS-CoV2 Virus," and "Indirect Antivirals Against SARS-CoV2 Virus."

To register for the event, please click here.

Wednesday, October 28th @ 10:30am ? 11:50am Eastern Time

Session Title: Direct Antivirals and Other Agents Against SARS-CoV2 Virus

Tarek Hassanein, M.D., F.A.C.P., F.A.C.G., A.G.A.F.,Participants: F.A.A.S.L.D., Professor of Medicine at University of California San Diego School of Medicine

Durect Corporation (DRRX) Aridis Pharmaceuticals (ARDS) Hepion Pharmaceuticals (HEPA) CohBar Inc (CWBR) Beyond Air (XAIR)